Janus Henderson Group
INDV icon

Janus Henderson Group’s Indivior Pharmaceuticals INDV Stock Holding History

Janus Henderson Group’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.51M Buy
49,450
+13,500
+38% +$446K ﹤0.01% 1495
2025
Q4 		$1.29M Sell
35,950
-41,025
-53% -$1.25M ﹤0.01% 1552
2025
Q3 		$1.86M Buy
+76,975
New +$1.61M ﹤0.01% 1363
2025
Q2 		– Sell
-40,546
Closed -$386K – 2454
2025
Q1 		$386K Hold
40,546
– – ﹤0.01% 2091
2024
Q4 		$520K Hold
40,546
– – ﹤0.01% 2012
2024
Q3 		$400K Hold
40,546
– – ﹤0.01% 2141
2024
Q2 		$636K Sell
40,546
-399,575
-91% -$7.21M ﹤0.01% 1867
2024
Q1 		$9.42M Buy
440,121
+54,750
+14% +$1.03M 0.01% 704
2023
Q4 		$5.82M Hold
385,371
– – ﹤0.01% 781
2023
Q3 		$8.37M Buy
+385,371
New +$8.79M 0.01% 697

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Janus Henderson Group's INDV Position: Q1 2026 in Review

Janus Henderson Group increased its Indivior Pharmaceuticals (INDV) stake by 38% in Q1 2026, buying an estimated $446K and bringing the position to 49,450 shares worth $1.51M. The position accounts for ﹤0.01% of the portfolio, ranked #1495.

Janus Henderson Group first reported a position in INDV in Q3 2023 and has held it in 10 quarters since. The position peaked at $9.42M in Q1 2024. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • Janus Henderson Group held 49,450 shares of Indivior Pharmaceuticals worth $1.51M as of Q1 2026.
  • Janus Henderson Group bought 13,500 Indivior Pharmaceuticals shares in Q1 2026, an estimated $446K.
  • Indivior Pharmaceuticals made up ﹤0.01% of Janus Henderson Group's portfolio in Q1 2026, its #1495 holding.
  • Janus Henderson Group first reported a position in Indivior Pharmaceuticals in Q3 2023 and has held it in 10 quarters since.
  • Janus Henderson Group's Indivior Pharmaceuticals position peaked at $9.42M in Q1 2024.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.